Brief: Enlivex Receives Regulatory Authorization To Expand Its Phase II Sepsis Trial Into Greece
07/12/2021 13:14
Dec 7 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES REGULATORY AUTHORIZATION TO EXPAND ITS
PHASE II
SEPSIS TRIAL INTO GREECE
* ENLIVEX THERAPEUTICS LTD - INTERIM RESULTS FROM PHASE II
TRIAL
ARE EXPECTED IN FIRST HALF OF 2022, AND TOP-LINE DATA ARE
EXPECTED BY YEAR-END 2022
Source text for Eikon: ID:nGNX2B9q6S
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment